CORMEDIX INC. REPORTS PROGRESS ON LOCK-IT 100 DATA REVIEW AND APPOINTS PAUL CHEW AS CONSULTANT ADVISOR CMO
Written by Sam Nelson on May 29, 2018
More than 75% of key data for Neutrolin® Phase 3…
More than 75% of key data for Neutrolin® Phase 3…
Anticipate Data Safety Monitoring Board review of interim analysis in…
Berkeley Heights, NJ – May 9, 2018 – CorMedix Inc. (NYSE…